ASPIRE Community of Practice

[ASPIRE Community of Practice @ASPIRE_CoP]

Join the @ASPIRE_CoP in person at #ASCO26 for “From Needs to Action: Connecting the Dots”: multidisciplinary discussion on IOTOX service lines, digital health, the ASPIRE Registry, AI innovation in irAEs & mentorship. @ASCO
📅 May 30, 2026
🕖 4:30–6:00 PM CST
📍Room S501abc

[ASPIRE Community of Practice @ASPIRE_CoP]

Live at #ASCO26: "Advancing ICI Therapy in High-Risk Populations" — rechallenge, transplant & combo toxicity.
📍E450a
🕖 4:45 - 6:00 PM CDT
Takeaway: @MattCarlino 
#immunotherapy #irAE

[ASPIRE Community of Practice @ASPIRE_CoP]

🔥 Exciting sessions to watch out for at #ASCO26!
🛡️ High-risk patients deserve immunotherapy too. How do we get them there safely?
📋 Advancing ICI Therapy in High-Risk Populations
🗓️ Mon Jun 1
🕖4:45–6:00 PM CT
📍 Room E450a
#irAEs #immunotherapy

[ASPIRE Community of Practice @ASPIRE_CoP]

Big morning for #irAE research at #ASCO26
📍Hall A is full of it!
A few we're watching: ICI rechallenge after irAE (#11127), CAR-T thyroid toxicity  (#11148), and pan-cancer genomic drivers of irAEs (#11132). Go see them!

[ASPIRE Community of Practice @ASPIRE_CoP]

A question for the #ASCO26 community: biggest unmet gap in managing checkpoint inhibitor pneumonitis? #irAE

[ASPIRE Community of Practice @ASPIRE_CoP]

🔥 Exciting sessions to watch out for at #ASCO26!
⚔️ Bispecifics are powerful — and so are their toxicities. Grab the management playbook.
📋 Management of Bispecific Antibody Toxicities
🗓️ Sun May 31
🕞 11:30 AM–12:45 PM CT
📍 Room E450a
#irAEs

[ASPIRE Community of Practice @ASPIRE_CoP]

🫁 Severe checkpoint inhibitor pneumonitis on steroids alone? Fresh phase 2 data on add-on ruxolitinib.
🎙️ Dr. Yan Xu · Peking Union Medical College Hospital
🗓️ Sun May 31 · 9:06 AM CT
📍 Room S403
#ASCO26 #irAEs #LungCancer

[Pauline Funchain @FunchainMD]

Cannot be more excited for the @ASPIRE_CoP Mentoring Academy and our very first class of irAE fellows, led by Noha Abdel Wahab @CleClinicMD #ASCO26 @afreenshariffmd @KMittalmd

[Pauline Funchain @FunchainMD]

Using all our resources for irAE: @afreenshariffmd identifies areas that AI can accelerate care for irAEs with agentic PRO and follow up @ASPIRE_CoP #ASCO26

[Pauline Funchain @FunchainMD]

irAE strategy at @BrownMedicine led by @mhadfield30 starts with clinical need, which led to a multidisciplinary tumor board and a concerted effort of subspecialists to move sample collection forward @ASPIRE_CoP @afreenshariffmd @KMittalmd #ASCO26

[Pauline Funchain @FunchainMD]

irAE strong 💪 Co chairs of @ASPIRE_CoP @KMittalmd and @afreenshariffmd review the growth of this international irAE consortium from humble beginnings in 2023-2024 @ProjDataSphere @ClevelandClinic + many more. Now 1 year of @ASPIRE_CoP with 243 members 📈

[Pauline Funchain @FunchainMD]

Building an IOTOX service line @kreynoldsMD @ASPIRE_CoP #ASCO26

➡️align with institutional priorities
➡️name your program
➡️meet regularly and invite broadly
➡️connect to the scientific community
➡️start somewhere, a pilot project etc
➡️partner with patients

@afreenshariffmd

[Pauline Funchain @FunchainMD]

irAE aficionados! In 15 mins at S501abc, come to @ASPIRE_CoP to solve problems, improve QOL, get patients to life saving immunotherapy. Come get this beauty of a badge ribbon ✨

@afreenshariffmd @KMittalmd @kreynoldsMD @lexmeara @thenasheffect @EladSharonMD

[ASPIRE Community of Practice @ASPIRE_CoP]

Happening now: the ASPIRE Community of Practice is underway in S501abc! 🤝
#ASCO26 #irAE

[ASPIRE Community of Practice @ASPIRE_CoP]

Starting in 1 hour: ASPIRE Community of Practice, 4:30 PM, S501abc. If you manage immune-related adverse events, this is your room. 🧡
#ASCO26 #irAE

[ASPIRE Community of Practice @ASPIRE_CoP]

Happening now at #ASCO26: "From Novel Agents to Novel Adverse Events" — toxicity profiles of emerging therapies, covering the patient perspective, eye toxicities & cutaneous toxicities. S403, 8 AM. 👀
#irAE #immunotherapy

[Dr Joseph McCollom DO @realbowtiedoc]

@ASPIRE_CoP @FunchainMD @NazliDizman @KMittalmd @afreenshariffmd Yes! 🙌 CoP time is the best time! @PallOncCoP #ASCO26

[Pauline Funchain @FunchainMD]

Your handy guide to irAE and immune toxicity sessions at #ASCO26 @ASPIRE_CoP 🤓

[ASPIRE Community of Practice @ASPIRE_CoP]

🧪 New agents → new adverse events. Time to get comfortable with the unfamiliar.
📋 From Novel Agents to Novel Adverse Events: Toxicity Profiles of Emerging Anticancer Therapy

🗓️ Sat May 30
🕒8:00–9:15 AM CT
📍 Room S403
#ASCO26 #irAEs #Immunotherapy

[ASPIRE Community of Practice @ASPIRE_CoP]

Thank you @realbowtiedoc
Cc: @FunchainMD @NazliDizman @KMittalmd @afreenshariffmd

[KMittaloncMD @KMittalmd]

Thank you @realbowtiedoc for sharing this list outlining all community of practice meetings at #asco26
Communities of practice are shared spaces bringing together @ASCO members. We at @ASPIRE_CoP look forward to meeting @OncMedEdCoP @IMG_Oncologists @PallOncCoP and many others!